Zimmer Biomet Holdings Inc. (ZBH) News
Filter ZBH News Items
ZBH News Results
|Loading, please wait...|
ZBH News Highlights
- For ZBH, its 30 day story count is now at 31.
- Over the past 19 days, the trend for ZBH's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
- SA, STAR and AMP are the most mentioned tickers in articles about ZBH.
Latest ZBH News From Around the Web
Below are the latest news stories about Zimmer Biomet Holdings Inc that investors may wish to consider to help them evaluate ZBH as an investment opportunity.
ZimVie Inc. (NASD:ZIMV) will replace Tabula Rasa Healthcare Inc. (NASD:TRHC) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 2. S&P 500 constituent Zimmer Biomet Holdings Inc. (NYSE: ZBH) is spinning off ZimVie in a transaction expected to be completed on March 1. Post spin off, Zimmer Biomet Holdings will remain in the S&P 500. Tabula Rasa Healthcare is no longer representative of the small-cap market space.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2022. The cash dividend of $0.24 per share is payable on or about April 29, 2022 to stockholders of record as of the close of business on March 29, 2022.
According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.
On February 7, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported earnings for the fourth quarter, posting an EPS of $1.95, missing estimates by $0.03. Zimmer Biomet Holdings, Inc.
Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.
Today is shaping up negative for Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) shareholders, with the analysts delivering a...
Worldwide Research on Regenerative Medicines Market Growth Prospects: 2022, Product Application, Current Trends, and Report Forecast to 2028 | Stryker Corporation, Zimmer Biomet Holdings
The research reports on "Regenerative Medicines Market" report give a detailed overview of the factors affecting the global scope of business. Information in the global Keyword market report provides forecast data for future market growth in global demand and supply.
Zimmer Biomet Opens ZBEdge Customer Experience Centre in Singapore to Drive Robotics and Medical Technology Transformation
SINGAPORE , Feb. 11, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today celebrated the opening of the ZB E dge Customer Experience Centre (CEC), a unique facility located at the company''s Asia Pacific regional headquarters in Singapore . The ZB E dge Customer Experience Centre is a state-of-the-art facility that showcases Zimmer Biomet''s latest technologies – ROSA ® robotics, mymobility ® digital health platform, OrthoIntel intelligence platform, OptiVu ™ Mixed Reality along with the company''s legacy orthopaedic implants. Serving healthcare professionals, business partners and surgeons in Asia Pacific region, the CEC aims to offer a collaborative environment that will enable Zimmer Biomet to partner with healthcare profess...
Several Wall Street analysts lowered their price targets for Zimmer Biomet (ZBH +7.2%), a day after releasing Q4 2021 earnings results that missed on both the top and bottom lines. While keeping his underweight rating, Wells Fargo's Lawrence Biegelsen lowered his price target to $111 from $124 (~1% downside). Baird's...
Zimmer Biomet Holdings (NYSE: ZBH ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 6 2 0 Last 30D 2 2 2 1 0 1M Ago 1 0 1 1 0 2M Ago 1 0 3 0 0 3M Ago 2 0 0 0 0 These 16 analysts have an average price target of $137.81 versus the current price of Zimmer Biomet Holdings at $111.54, implying upside. Below is a summary of how these 16 analysts rated Zimmer Biomet Holdings over the past 3 months. The greater the number of bullish ratings, the Full story available on Benzinga.com